Aurobindo Pharma, a global pharmaceutical company, announced a strong performance in Q4FY24, with growth across all business segments.
Key Financial Highlights:
Revenue from Operations: Increased by 17.1% YoY to ₹7,580 crore.
US Formulations Revenue: Increased by 21.6% YoY to ₹3,588 crore (USD 432 million).
Europe Formulation Revenue: Increased by 10.4% YoY to ₹1,832 crore (EUR 203 million).
Growth Markets Revenue: Increased by 49.5% YoY to ₹852 crore (USD 103 million).
ARV Revenue: Increased by 31.5% YoY to ₹238 crore (USD 29 million).
API Revenue: Remained flat YoY at ₹1,019 crore (USD 123 million).
EBITDA (before Forex and Other income): ₹1,687 crore.
EBITDA Margin: 22.3%.
R&D Spend: ₹392 crore, 5.2% of revenues.
Net Profit: ₹909 crore, vs. ₹506 crore in Q4FY23.
Basic & Diluted EPS: Grew by 79.5% YoY to ₹15.51 per share.
Key Points:
Growth Across the Board: Aurobindo Pharma witnessed significant growth in all its business segments during Q4FY24.
Strong US Performance: The company's US formulation business performed exceptionally well, driven by new product launches and stable pricing.
Improved Capacity Utilization: The increased capacity utilization led to higher operating efficiencies, contributing to the overall growth in profitability.
Research & Development: The company continued to invest in R&D, reflecting its commitment to innovation.
Positive Outlook: The company is confident of continuing its growth trajectory in the upcoming year, while stabilizing the operations of recently commercialized facilities.
Management Commentary:
K. Nithyananda Reddy, Vice-Chairman and Managing Director, expressed satisfaction with the company's strong performance in Q4FY24 and the full year. He attributed the growth to the expansion into new markets, product launches, stable pricing, and improved operating efficiencies.
Additional Resources:
ICICI Direct Analysis: https://www.icicidirect.com/research/equity/rapid-results/aurobindo-pharma-ltd
Aurobindo Pharma Investor Relations: https://www.aurobindo.com/investors/results-reports-presentations/results-announcements
Comentarios